Biotechnology

Vibrant Wellness Advances Food Sensitivity Research With New Clinical Trial

August 22, 2024 11:00 AM

Pioneering Study Aims to Inspire Further Research into Food Sensitivity Testing SANTA CLARA, CA / ACCESSWIRE / August 22, 2024 / Vibrant Wellness, a leader in specialty lab testing, announced the release of new research on food sensitivity, highlighting their ongoing commitment to personalized wellness and longevity. The study, currently in preprint and awaiting peer-review, is a critical step toward remedying the need for more research in the...

Read more

MRES: M2Bio Food and Beverage Refocuses Strategy: Expanding Beyond CBD to Reach Global Consumers

August 22, 2024 10:00 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / August 22, 2024 / The Institute of Biomedical Research Corp. (OTC PINK:MRES), a pioneering nutraceutical biotechnology company that delves into the innovative realm of plant-based medicines, healthy food products, and sustainable packaging solutions, is pleased to announce the following updates with its M2Bio Food and Beverage division: M2Bio Food and Beverage, known for its premium, healthy, and...

Read more

Interim Report April-June 2024

August 22, 2024 2:30 AM

STOCKHOLM, SE / ACCESSWIRE / August 22, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, August 22, 2024- Vicore Pharma Holding AB (STO: VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for second quarter 2024. "This quarter, we are excited to report promising results from our Phase 2a trial evaluating buloxibutid in patients with...

Read more

Asia Green Biotechnology Corp. Announces Termination of Letter of Intent

August 21, 2024 6:55 PM

CALGARY, AB / ACCESSWIRE / August 21, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announced today that it has elected to the terminate the previously announced agreement dated February 9, 2024, pursuant to which the Company was to acquire all of the issued and outstanding shares in two private companies being Burton Growers Ltd. and Green-Sight Agri-Holdings Inc. Management of Asia Green has cited delays in obtaining...

Read more

CB Scientific, Inc. Announces Voluntary Delisting from OTCQB Venture Market

August 20, 2024 10:30 AM

LAS VEGAS, NV / ACCESSWIRE / August 20, 2024 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced today that the Company is voluntarily delisting its common stock ("Common Stock") from trading on the OTCQB Venture Market. Delisting from the OTCQB Venture Market will have no impact on Company's Common Shares which...

Read more

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

August 19, 2024 9:00 AM

30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab) Kineta anticipates the trial to be fully enrolled by the end of 2024 TAMPA, FL and SAN DIEGO, CA / ACCESSWIRE / August 19, 2024 / TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company...

Read more

Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05

August 19, 2024 7:00 AM

FDA Approval of Nypozi™ and FDA BLA Acceptance of TX-05 Further Validates Tanvex's Expertise in Biologics Development and Manufacturing. SAN DIEGO, CA / ACCESSWIRE / August 19, 2024 / Tanvex BioPharma USA, Inc. ("Tanvex" or the "Company"), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, recently announced that the U.S. Food and Drug Administration (FDA) approved NYPOZI™...

Read more

uBriGene Biosciences Congratulates Strategic Partner InnoVec Biotherapeutics on FDA Clearance of IND for IVB103, an AAV-Based Gene Therapy

August 19, 2024 7:00 AM

-Super Speed of Only Nine Months GERMANTOWN, MD / ACCESSWIRE / August 19, 2024 / uBriGene Biosciences (uBriGene), a global CDMO leader, is excited to announce that its strategic partner, InnoVec Biotherapeutics, has received FDA clearance for its Investigational New Drug (IND) application for IVB103, an AAV-based gene therapy for neovascular age-related macular degeneration (nAMD). This crucial nod from the FDA marks the official launch of...

Read more

Notice of Annual General Meeting in Biovica International AB

August 16, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / August 16, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting to be held on Tuesday 17 September 2024, at 10.00 CET in Conference Hubben's premises on Dag Hammarskjölds Väg 38 in Uppsala. Right to attend the general meeting Shareholders wishing to attend the annual...

Read more

Cadiz to Present at the Q3 Virtual Investor Summit Microcap Event

August 15, 2024 6:00 PM

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Cadiz, Inc. (NASDAQ:CDZI)(NASDAQ:CDZIP) ("Cadiz" or the "Company"), a California water solutions company, today announced that management will present virtually at the Investor Summit Microcap Event on Tuesday, August 20, 2024. The Company will be available for 1-on-1 meetings throughout the day in addition to their presentation. Event: Q3 Investor Summit Date: August 20, 2024 Presentation Time: 9:30...

Read more

OS Therapies Reports Second Quarter 2024 Financial Results

August 15, 2024 8:30 AM

OS Therapies, Inc. (NYSE American:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today reported financial results for the second quarter of 2024 ended June 30, 2024. As of the date of our successful initial public offering (IPO) that occurred on July 31, 2024 on the NYSE American stock exchange, the Company successfully converted all of its outstanding preferred shares and...

Read more

Indica Labs Announces Suite of HALO AI Apps to Power Life Sciences Image Analysis Workflows

August 15, 2024 8:00 AM

Indica Labs today announces expansion of AI capabilities for life science with the launch of HALO AI Apps, pre-trained tissue classifiers and cell phenotypers for tissue-based research applications. HALO AI Apps demonstrate powerful image analysis capabilities across a variety of tissue types out-of-the-box and can be further trained, tuned, and improved upon by customers with their own images and data. In total, 11 new apps are available with...

Read more

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

August 14, 2024 10:50 PM

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. Event: Q3 Investor Summit Date: August 20th, 2024 Presentation Time: 2:00 pm ET Location: https://www.webcaster4.com/Webcast/Page/3062/51117 The...

Read more

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

August 14, 2024 4:15 PM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the second quarter ended June 30, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our FDA-designated Breakthrough Therapy product candidate,...

Read more

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)

August 14, 2024 9:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today provided an update on the U.S. Food and Drug Administration (FDA) premarket approval (PMA) application status for its lead product, a surgical replacement venous valve called the VenoValve. Four (4) out of five (5) modules that comprise the VenoValve PMA application have now been submitted,...

Read more

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

August 14, 2024 8:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2024. "We remain confident in the potential of our DNase-based oncology platform and continue to advance our preclinical studies with data expected before year end. Looking ahead, we are...

Read more

dermaFIT Muscle Cream: The World’s First and Only Muscle Retention Cream Now Available at dermaFIT.com

August 13, 2024 9:00 AM

FULLERTON, CA / ACCESSWIRE / August 13, 2024 / EX Healthcare, a leading skin healthcare company, is proud to announce the launch of dermaFIT, the world's first and only muscle retention cream, now available for purchase at dermaFIT.com. dermaFIT Muscle Retention Cream dermaFIT's three types of muscel retention cream: Strength for daily protection, Extra-Strength for double support and Sculpt for slimming. Developed by EX Healthcare, dermaFIT is...

Read more

Lifeloc Reports Second Quarter 2024 Results

August 8, 2024 4:18 PM

WHEAT RIDGE, CO / ACCESSWIRE / August 8, 2024 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2024. Second Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.387 million in the second quarter of 2024, resulting in a quarterly net loss of $(298) thousand, or $(0.12) per...

Read more

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

August 8, 2024 8:25 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides a summary of its successful symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company's symposium illustrated the current landscape of...

Read more

Scorpius Holdings, Inc. Announces Pricing of Public Offering

August 6, 2024 9:25 PM

DURHAM, NC / ACCESSWIRE / August 6, 2024 / Scorpius Holdings, Inc. (NYSE American:SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of an underwritten public offering of 12,500,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being offered at a public offering...

Read more